Arthritis is a multifactorial degenerative disease of the joints marked with articular cartilage degradation and is characterized by a series of molecular events leading to irreversible damage. Cartilage, which is actually a dynamic structure made up of proteins and proteoglycans, interacts with chondrocytes and conduct signals to regulate the behavior of the chondrocytes. However, an imbalance in the metabolism of extracellular matrix (ECM) components or an error in gene expression at transcription, translation, or posttranslational levels would end up in altered homeostasis of the cartilage leading to the joint pathology. Degradation of the cartilage is believed to be principally mediated by proteases and glycosidases particularly matrix metalloproteases (MMPs), aggrecanases and hyaluronidases. MMPs degrade collagen of ECM while, aggrecanases cleave proteoglycan aggrecan. The major substrates for glycosidases are hyaluronan and other glycosaminoglycans, which serve as lubricants at the joint and also regulate the expression and functioning of MMPs. The molecular expression and regulation of these enzymes are thus shown to be critical in arthritis perpetuation and therefore have emerged as potent therapeutic targets in the management of arthritis. In view of this, the present review focus on the involvement of cartilage degrading enzymes and cartilage degradation products in arthritis pathophysiology.
Introduction
Inflammatory arthritis is a highly prevalent and common joint disorder of humans, and is considered to be a major public health crisis [1, 2] . It is characterized by chronic inflammation mainly targeting the synovial membrane and articular cartilage, leading to joint damage and destruction. Thus, degradation of articular cartilage is considered the REVIEW hall mark of progressive arthritis [3] . Articular cartilage is an imperative component of bone joint that endows it with high elasticity and strength to withstand compressive load on the joints. It is mainly constituted with a highly organized network of type-II-collagen fibrils inter-linked with small proteoglycans and proteoglycan aggregates. The proteoglycan aggregates are in turn made up of noncovalently linked hyaluronan (HA) and aggrecan, which are often stabilized by link proteins. Cartilage is actually a vibrant structure that interacts with chondrocytes to regulate its behavior through feedback signals. However, an imbalance in the metabolism of ECM components or an error in gene expression, transcription, translation, or posttranslational modification would end up in the altered homeostasis of the cartilage leading to the joint pathology [4] [5] [6] . The pathological disorders targeting ECM molecules may induce an unregulated immune response and trigger a chronic inflammatory process causing joint injury. Degradation of the cartilage is principally mediated by hydrolytic enzymes like matrix metalloproteinases (MMPs), glycosidases (endo and exo) and aggrecanases, whose activities are regulated at transcriptional/translational/post-translational levels (Fig  1) . In addition, free radical species and pro-inflammatory cytokines are also known to play a role in cartilage deterioration (Fig 2) .
The MMPs specifically target type II collagen, a major constituent of cartilage, thus significantly altering the structural and functional stability of the articular cartilage. In addition, proteases also expose the cleavage sites for endo-and exoglycosidases by producing glycopeptides [7, 8] . Hyaluronidase, an endoglycosidase enzyme that cleaves glycosidic linkages within the glycosaminoglycan or proteoglycan oligosaccharide chain to release oligosaccharide chains [9] . On the other hand, lysosomal exoglycosidases such as N-acetyl-β-hexosaminidase (HEX), β-galactosidase (GAL) and β-glucuronidase (GluA) release monosaccharides from the non-reducing terminals of glycoprotein oligosaccharide chains, glycolipids and proteoglycan glycosaminoglycans of synovial tissue, articular cartilage and synovial fluid [10] . In addition, MMP and HAases-generated end-products act as pro-inflammatory signaling molecules to operate cluster of differentiation 44 (CD44) and toll like receptor (TLR-4), which are involved in nuclear factor-kappa B (NF-κB) pathway and aggravate inflammation.
Thus, cartilage degrading enzymes have emerged as potent therapeutic targets in the management of progressive arthritis. In view of this, the present review focuses on the involvement of MMPs, glycosidases and aggrecanases in arthritis pathology, as well as role of cartilage degradation products in disease perpetuation. The proteolytic cleavage of the major ECM components of the cartilage is mainly mediated by a group of MMPs, which are actually synthesized by chondrocytes and synovial cells in response to inflammatory stimuli. MMPs play a key role in the degradation of cartilage and are also involved in numerous physiological and pathological processes. They are characterized by the presence of a metal ion within the active site, which is imperative for their catalytic activity. Members of the MMP family include the classical MMPs, the membrane-bound MMPs (MT-MMPs), the ADAMs (a disintegrin and metalloproteinase; adamlysins) and the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motif) [11, 12] . In a majority of instances, the metal ion in the active site is Zn 2+ , however manganese/ nickel/ cobalt may also be present. In humans, the majority of MMPs are Zn 2+ -endopeptidases distributed in clan MA (M3, M10, M12, M13, M41, M43 and M48 families), clan ME (M16 family), clan MJ (M19 and M38 families), clan MK (M22 family) and clan MM (M50 family). Basically, MMPs cleave peptide bond similar to that reported for serine and cysteine proteinases, but few groups act via electrophilic attack. The Zn 2+ ion at the catalytic site of MMPs is coordinated by three histidine residues and a water molecule as the fourth ligand in the absence of the substrate/inhibitor [13, 14] .
Matrix metalloproteinases (MMPs)
Under normal physiology, MMPs monitor the synthesis and secretion of cytokines, growth factors, hormone receptors and cell adhesion molecules. They also play an important role in growth and development, morphogenesis and tissue remodeling. They also contribute in the progression of pathological disorders like arthritis, cardiovascular disease, neurodegenerative diseases, multiple sclerosis, stroke, allergies and cancer metastasis [15, 16] . In case of arthritis, MMPs execute proteolytic cleavage of cartilage and ECM. Exhaustive studies on transcriptional, translational and post-translational regulation of the MMP family have focused mainly on the understanding of disease specific and tissue specific expression of MMPs. It is well-documented that MMP-1, -3, -9, and -13 are up-regulated during arthritis. Basically, MMP-1 produced by synoviocytes, degrades type I, II and III collagen while, MMP-3 degrades specifically type III collagen and proteoglycans of cartilage. Similarly, MMP-9 acts upon type IV and V collagens and MMP-13 released by chondrocytes, degrades type II collagen more potentially than type I and III. Besides, MMP-2, -8, -10, -12, -14 and -19 which are largely expressed by synoviocytes, are also found to be up-regulated in arthritis and are believed to degrade non-collagenous proteins of the matrix, thus ensuring complete degeneration of cartilage. Nevertheless, it is also reported that these MMPs contribute to the propagation of arthritis-induced angiogenesis as well [17, 18] . Furthermore, MMP -1, -2, -3, -9, -12, -3 and -14 have also been shown to play a role in bone resorption by osteoclasts. However, cathepsin K a cysteine proteinase is the major enzyme that functions in the acidic phagolysosomal resorption zone of the osteoclast [19, 20] . But still MMPs degrade a number of non-collagenous bone matrix proteins and thus clearly play a role beyond cartilage degradation.
The tissue specific and disease specific expression of MMPs is tightly regulated at the gene level. During arthritis, MMP-2 and MT1-MMP are expressed continuously, which might be due to fact that these genes do not contain a TATA box in the promoter region whereas, MMP-1,-3, -9, and -13 are induced by IL-1 β/TNF-α stimuli [21, 18] . It has been shown that MMP transcription is mainly regulated by a protein complex composed of cFos/c-Jun heterodimers or c-Jun/c-Jun homodimers called activator protein 1 (AP-1) binding site. The promoters of MMP-1, -3, -9, and -13 contain AP-1 site, which is critical for their expression. Furthermore, IL-1 β/TNF-α regulates gene expression of MMPs via signal transduction involving mitogen-activated protein kinases (MAPKs) pathway. The DNA bonding AP-1 complex is activated by the c-Jun Nterminal kinase (JNK) by phosphorylating c-Jun. AP-1 also induces the synthesis of c-fos and c-jun mRNAs upon inflammation (Fig 3) [22] . Further, MAPK and p38 also activates other factors necessary for the synthesis of AP-1 and E26-transformation specific (Ets) proteins suggesting that MAPK pathways are important signaling mediators of inflammatory cytokines and target the AP-1 and Ets sites in the MMP promoters. In addition, NF-κB is also known to play a critical role in controlling MMP expression during arthritis perpetuation. Basically, NF-κB is a dimer containing p50 and p65 subunits and will be inactive in the cytoplasm when bound to the inhibitor of NF-κB (IκB). Upon stimulation with IL-1β/TNF-α, phosphorylated IκB is targeted for destruction in the proteosome. The IκB dissociated p50 and p65 subunits translocate to the nucleus to activate transcription by binding promoter gene (consensus sequence = GGGACTTTCC). The transcriptional induction of MMP-1, -3, and -9 genes requires NF-κB activation and their promoters contain canonical binding sites for NF-κB as well. However, MMP-13 promoter lacks NF-κB binding site but inhibition of NF-κB blocks MMP-13 activation by inflammatory cytokines suggesting the involvement of NF-κB in transcriptional regulation of MMP-13. Further it has been shown that the transcription factor core binding factor alpha-1 (CBFA-1 also known as Runx-2) is also essential for MMP-13 expression in osteoblasts and chondrocytes [23, 24, 22] .
Thus, it is of prime importance to regulate the expression of MMPs in the pathogenesis of arthritis and is considered to be one of the potential targets in preventing arthritis. In the system, MMPs are regulated by endogenous inhibitors, including tissue inhibitors of metalloproteinase (TIMPs), α2-macroglobin, heparin and the reversion-inducing cysteine-rich protein with kazal motifs (RECK). In humans, four different TIMPs have been identified (TIMP-1, -2, -3 and -4) among which, TIMP-1 and -3 are glycoproteins, but TIMP-2 and -4 do not contain carbohydrates.
They inhibit all MMPs and proinflammatory cytokines in the joint and thereby prevent tissue damage. However, during arthritis or other pathologic conditions their regulation is completely altered [22, 25] .In view of this, enormous effort has been put to come out with potential MMP inhibitors either by chemical synthesis or herbal-derived products. Recently, a number of MMP inhibitors derived from herbal products are shown to suppress arthritis and thus seem very promising in arthritis management [26] .
Hyaluronidases
The hyaluronidases (HAase) are a group of enzymes that regulate HA metabolism, and are widely distributed throughout the animal kingdom. HA is actually a megadalton polycaccharide, which is an important component of cartilage and functions as aggrecan immobilizer in cartilage and also as a lubricant in the joints. It is characterized by a repeating disaccharide of Nacetylglucosamine and D-glucuronic acid, whose turnover is regulated by HAase and hyaluronan synthases (HAS). Based on biochemical analysis and end products formed, HAases have been classified into three different groups like mammalian HAase, leech HAase (hyaluronate-3-glycanohydrolases) and microbial HAase [27] . Mammalian HAase (E.C. 3.2.1.35) is endo-β-N-acetlyhexosaminidase that arbitrarily cleaves β-1-4 glycosidic linkages in HA, chondroitin and chondroitin sulfates (A and C), and release even numbered oligosaccharides (tetra and hexa) as the major end products with N-acetylglucosamine at the reducing terminal. These HAases have both hydrolytic and transglycosidase activities [28] . Presently, about six human HAase gene sequences have been deduced that share 40% of their identity with one another and are generally referred to as hyaluronoglucosaminidase (HYAL) genes. HYAL1, HYAL2 and HYAL3 are located on chromosome 3p21.3 and a set of HYAL4, PHYAL1 (a pseudogene), and sperm adhesion molecule 1 (SPAM 1) are clustered in a similar fashion on chromosome 7p31.3. Hyal1 and Hyal2 are the major HAases expressed in human somatic tissues [29] .
Several studies have reported elevated levels of serum HA as well as increased serum HAase activity during arthritis. Among five homologous isozymes in humans, HYAL1, -2, and -3 are thought to be expressed in synovium and involved in HA degradation. It has been shown that HYAL1, HYAL2, HYAL3 and PH-20 are expressed in both human and bovine chondrocytes [30, 31] . Similarly, HYAL2 and, to a greater extent, HYAL3 mRNA levels were shown to up-regulated in cartilage explant cultures upon treatment with cytokines like IL-1 and TNF leaving HYAL1 mRNA levels unaltered [30] . Majority of HA is cleared from the circulation by endocytosis in the lymph nodes and liver, via the HA receptor for endocytosis (HARE). It is well-documented that HA in the cartilage is degraded by HYALs intracellularly or extracellularly, which is partially dependent on its association with aggrecan. Free HA (not associated with aggracan) or HA linked to small aggrecan fragments are degraded within lysosomes by CD44 mediated internalization. Whereas, HA complexed with high molecular mass or intact aggrecan is degraded outside the cell as it cannot be internalized [32] .
Non-enzymatic HA degradation is achieved by reactive oxygen species (ROS) and reactive nitrogen species (RNS) yielding various intermediate end products under oxidative conditions [38] . ROS and RNS accumulate in a number of pathological disorders including arthritis, chronic obstructive pulmonary disease (COPD), wound healing, asthma and malignancy [39] [40] [41] . For instance, during arthritis, fibroblasts, chondrocytes and inflammatory cells such as neutrophils and macrophages are significant sources of ROS/RNS [42] . The reactions of O2
•-with many different biological macromolecules, including HA, have been studied in detail. The superoxide anion radical is both oneelectron oxidant and reductant. No reduction in the viscosity of HA solution (as a measure of HA degradation) is observed in presence of xanthine oxidase, which is a source of O2
•-. In contrast, significant HA depolymerization is observed in the presence of ferritin-bound iron, indicating that ferritin could catalyze the Haber-Weiss reaction leading to the formation of highly damaging hydroxyl radicals. Therefore, HO • but not O2 •-is responsible for ROS-mediated HA degradation. Similarly, pure H2O2 is not capable of reacting with HA. However, ferrous and other low-valent transition metals decompose H2O2 and generate HO
• radicals leading to HA degradation [43] .
The glycosidic linkage between two pyranosyl rings in the HA polymer is a preferred reaction site for HO • radicals. This has been demonstrated using irradiated HA, both in solid state as well as aqueous solution. The reaction starts with formation of the alkyl radical from C-H group. Addition of molecular oxygen to the alkyl radical generates the corresponding peroxyl radical and eliminates O2 •-leading to the formation of the corresponding carbonyl compound by cleaving intermediate radicals. HOCl is an important mediator of inflammation, generated by the enzyme myeloperoxidase (MPO) in vivo. The glucosamine moiety of HA is shown to be the most relevant site of reactivity for HOCl. However, the glucuronic acid moiety is quite inert against the action of HOCl. In addition, NaOCl oxidizes HA and generates meso-tartaric acid, whereas the Fenton reagent yields arabinaric acid and glucaric acid by the oxidation of HA. Peroxynitrite is also capable of degrading HA by generating HO
• radicals. In summary, a variety of processes lead to ROS and RNS production, including many inflammatory conditions, resulting in the non-enzymatic degradation of HA in tissues. Strategies for the commercial synthesis of HA must therefore include ways to protect HA from ROS and RNS for clinical and other applications [44, 43, 38, 39] .
Hyaluronan synthase
Loss of HA during the progression of arthritis is due to the combined action of HAases and HAS, as both these enzymes determine the rate of HA degradation or synthesis respectively in the joint [31] . High molecular weight HA (HMWHA) has been demonstrated to effectively attenuate fibronectin fragments/cytokines-induced cartilage degradation. In addition, HA has been shown to act as a joint pain reliever by masking free nerve ending organelles in vivo. Thus, HMWHA has been considered an indispensable constituent that maintains articular cartilage homeostasis [33] . Several studies have reported the reduced levels of HMWHA in the synovial fluids of arthritic patients indicating the role of HA and its stipulated metabolic regulation by HAases/HAS in the pathogenesis of arthritis. In human knee synovium, HA is synthesized by a set of three HASs located at the synovial membrane, which are encoded by three distinct genes. Stable transfectants of HAS1 and HAS3 produces HA with molecular weights of 2 x 10 5 Da -2 x 10 6 Da, whereas stable transfectants of HAS2 produces HMWHA with an average molecular weight >2 x 10 6 Da. In human synovium, HAS1 and HAS2 are the major HASs expressed and are found to express significantly high total HAS mRNA than human articular cartilage. Both human articular cartilage and articular chondrocytes are found to express the HAS2 isomer. It has been shown that antisense oligonucleotides-treated (block HAS2) chondrocytes fail to produce sufficient HA, formation of pericellular matrix and aggrecan immobilization. Whereas, the over expression of HAS2 upturns the above events with increased secretion of HMWHA, which suggests the significant role of HAS2 and HA in the cartilage homeostasis. Furthermore, reduced expression of both HAS1 and HAS2, which ultimately results in the decreased levels of HA, was observed in arthritic synovium. The importance of maintaining size and concentration of HA in synovial fluid was demonstrated in viscosupplementation studies where intra-articular injection of HMWHA suppressed the pain in inflamed joints and promoted cartilage remodeling. It was also observed that the benefits of intra-articular HA are consistent with down-regulation of HAS2 in an inflammatory model of arthritis and up-regulation of HASs during autologous chondrocyte transplants driven cartilage repair. Thus, synovial expression of HAS and HMWHA greatly contribute towards the pathogenesis of arthritis and other cartilage defects [34, 33] .
Aggrecanases
Aggrecans occupy the interstices of the collagen meshwork of articular cartilage by forming complex proteoglycan aggregates interacting with HA and some link proteins. Loss of aggrecan from the cartilage is a critical event in the pathogenesis of arthritis as they can act independent of MMPs [35] . The process begins initially at the surface of the joint and progresses in to the deeper zones, which is preceded by degradation of collagen fibrils. Basically, aggrecan is a negatively charged long polysaccharide chain that consists of a core protein (250kDa) covalently linked to chondroitin sulfate and keratan sulfate glycosaminoglycan (GAG) chains. It mainly consists of three globular domains, G1-through which it interacts with HA, G2 and G3 as the C-terminal molecules that are highly substituted with the GAG. The presence of a large number of negatively charged groups on the GAGs of aggrecan imparts a high osmotic pressure in the tissue, which in turn endows the tissues with the inherent properties of compressibility, resilience and strength to resist compressive loads [36, 37] .
The aggrecans are enzymatically degraded by a class of proteolytic enzymes called aggrecanases that are members of the ADAM protein (A Disintegrin And Metalloprotease) family. Sandy et al., [45] were the first to report the aggrecan cleavage at either Asn341-Phe342 or Glu373-Ala374 in IL-1 treated bovine articular cartilage.
However, aggrecanase 1, the first aggrecanase and subsequently aggrecanase 2 were reported by Tortorella et al., [46, 47] and are presently known as ADAMTS-4 and ADAMTS-5 respectively. These are zinc metalloproteinases, whose structure and domain arrangements are homologous to ADAMTS proteins. They are highly specific to aggrecans and do not act on other ECM components like collagens, fibronectin and thrombospondin, and do not cleave general proteinase substrates such as casein and gelatin as well. This might be due to their non-catalytic domains, as it has been demonstrated that ADAMTS-4 proteinase domain alone does not cleave aggrecan core protein suggesting the necessity of thrombospondin type I domain in the recognition and cleavage of aggrecans. It was also showed that MMP-cleaved interglobular domain (IGD) is not vulnerable to aggrecanase, whereas aggrecanase-cleaved IGD is hydrolyzed by MMPs suggesting that aggrecanases are the initial enzymes responsible for aggrecan degradation, which is followed by MMPs. It also suggested that, aggrecanases can act independent of MMPs, and thus are the potent targets in the development of antiarthritic therapeutic strategy. Besides, the gene regulation of aggrecanase-1 both in human synovium and fibroblast-like synovium (FLS) was demonstrated by Yamanishi et al., [48] . Cytokine TGF-β is able to induce aggrecanase 1 expression in synoviocytes, but does not affect aggrecanase 2 suggesting the cytokine-independent expression of aggrecanase 2 [48] . Furthermore, elevated activities of ADAMTS4 and ADAMTS5 have been reported in arthritic synovium and cartilage. It is also demonstrated that proinflammatory cytokines such as TNF-α and IL-1 produced by synovial macrophages up-regulate ADAMTS4 in an NF-κB-dependent manner. The 5' flanking region of ADAMTS4 is shown to possess NF-κB binding sites. Thus, pro-inflammatory cytokines play an important role in the activation of aggrecanases via NF-κB pathway.
Exoglycosidases
Since 1970 several studies have reported elevated levels of glycosidases in joint diseases. Arthritis is also typified by a decreased concentration of glycosaminoglycans (GAG) that has been attributed to the increased activity of endo and exo-glycosidases. Exoglycosidases such as Nacetyl-β-hexosaminidase (HEX), β-glucuronidase (GluA), β-galactosidase (GAL), α-mannosidase (MAN) and α-fucosidase (FUC), act on non-reducing terminals of oligosaccharide chains of proteoglycans releasing monosaccharides from the synovial tissue and articular cartilage. They degrade glucoconjugates within the lysosome at an optimum pH ranging from 4.3 to 5.5 [49, 50] .
The exoglycosidases (protein part) are actually synthesized in the rough endoplasmic reticulum and later transported to lysosomes [51] . The lysosomal enzymes are secreted into the extracellular fluid from the cell or from the lysosomes via the endosomes and Golgi. The exoglycosidase secretion is regulated at gene level by a small Ras-related GTP-binding protein Rho p21. It has been also shown that the exoglycosidases from mast cells is induced by an IgE mediated increase in intracellular Ca² + [51] . The HEX releases terminal N-acetylhexosamines, whereas GAL releases terminal galactose [52] , from the non-reducing terminal of oligosaccharide chains of glycoproteins, glycolipids and keratan sulfate. Besides, MAN releases mannose from N-linked sugar chains of glycoproteins, while FUC degrades various fucose-containing oligosaccharide chains of glycoproteins and glycolipids [52] . The GluA releases glucuronic acid residues from the nonreducing terminal of glycosaminoglycans [50] .
Further it is reported that HEX is the major glycosidase in synovial fluid of patients with osteoarthritis released by chondrocytes. HEX activity in the synovial tissue of arthritic patients was approximately 10-fold higher than in the normal synovial tissue while, GluA, GAL, MAN and FUC were moderately elevated. Basically, HEX (EC 3.2.1.52) is lysosomal hydrolases, which catalyzes the hydrolysis of non-reducing N-acetyl-L-D-glucosamine and N-acetyl-L-D-galactosamine terminal residues of GAGs, glycoproteins and gangliosides, including HA and sulfates of chondroitin, keratan and dermatan. In humans two isoenzyme for HEX has been identified, HEX A and HEX B. HEX A is a heterodimer that consist of K and L subunits and can hydrolyze both neutral and negative-charge substrates, mainly sulfated substrates in contrast; HEX B is a homodimer that consists of two L subunits can only hydrolyze the neutral substrates. Both isoenzymes recognize terminal N-acetylglucosamine and Nacetylgalactosamine, but only HEX A recognizes 6-sulfated residues. The expression of exoglycosidases is mainly regulated by the inflammatory cytokines mainly IL-1β and TNF-α in the cartilage. It was demonstrated that IL-1β stimulated arthritic synoviocytes resulted in elevated HEX and HEX A activity. However, the mechanism of selective stimulation of HEX by IL-1β is still not clear. It is postulated that IL-1β selectively up-regulates HEX expression and facilitates intra-compartmental transport of HEX from lysosomes into the extracellular space by modifying the mannose-6-phosphate receptor system [53] . Of late, significant activity and gene expression of HEX D is also reported in the extracellular vesicles released by human synovial fibroblasts. Thus, suggested that the new HEX D activity may significantly contribute to the overall local exoglycosidase activity [54] . Similarly, GluA is yet another enzyme responsible for GAG degeneration although is expressed as high as HEX in the synoviocytes of arthritic patients. Human β-glucuronidase catalyzes hydrolysis of β-D-glucuronic acid residues from the nonreducing end of GAGs present in the cartilage. Thus inhibition of exoglycosidases would be a novel approach to prevent arthritis by diminishing cartilage GAG degradation and hence would be novel strategy to treat arthritis.
Overall, the solid evidence for the action of MMPs, HAases aggrecanases and exoglycosidases in the degradation of cartilage and pathogenesis of arthritis strongly commands for the emergency in the development of their inhibitors for a prolific therapeutic approach. Till date, several potent inhibitors have been reported to target MMPs, HAase and aggrecanases so far (Table 1) .
Cartilage degraded products
The enzymatic and non-enzymatic degradation of HA releases HA oligomers (fragments), which are also known to be potent stimulators of inflammatory cytokines and adhesion molecules [55] . HA oligomers are shown to increase cell migration and gene expression of MMP-9 and MMP-13 in Lewis Lung Carcinoma (3LL) cells and primary embryonic fibroblasts [56] . Several studies using activated macrophages have demonstrated that HA fragments induce the expression of chemokine genes such as, macrophage inflammatory protein (MIP)-1α, MIP-1β, crg-2, RANTES and monocyte chemotactic protein-1 (MCP-1), the functions of which are vital in triggering and maintaining inflammatory responses [57] . Furthermore, interaction of HA oligosaccharides with bovine chondrocytes and human articular chondrocytes is reported to stimulate the expression of HAS-2, MMP-3, MMP-13 and iNOS [58, 59] . The HA fragment mediated activation of NO production has been shown in macrophages, rat liver endothelial cells, Kupffer cells, T-24, HeLa, MCF7, and J774 cells. The stimulatory effects of HA fragments are often shown to be mediated through NF-κB activation. The pro-inflammatory HA fragments are found to mediate signals through toll like receptor 4 (TLR-4) in dendritic cells and endothelial cells [60, 61] . Recent studies confirm that HA oligomers require MyD88, TLR4 and TLR2 both in vitro and in vivo to initiate the inflammatory response in acute lung injury [62] . Ohano et al. have shown that hexasaccharides behave as antagonists to HMWHA by interfering with normal bovine chondrocyte cell-matrix interactions including assembly of pericellular matrix. Further, expression of transcription factors such as AP-1, NF-κB, p53, Sp1, and Stat4 is markedly up-regulated in bovine articular chondrocytes after treatment with hexasaccharides [63] . Besides, the major cartilage degradation product fibronectin is reported to stimulate cartilage chondrolysis. The COOH-terminal of heparin binding fibronectin fragment has been found to induce cartilage degradation [64] . It is also demonstrated that depletion of fibronectin fragments from synovial fluid can reduce cartilage destructing activity whereas, injection of fibronectin fragments induce cartilage destruction in rabbit knee. It is shown that central cell binding fibronectin fragments induce expression of MMP-1 and MMP-3 from synovial fibroblasts [65] . It also stimulates the production of MMP-13 in human chondrocytes. Further, NH2-terminal gelatinbinding fibronectin is found to stimulate MMP-13 and MMP-3 production in porcine chondrocytes [66] . On the other hand heparin-binding COOH-terminal fibronectin fragment stimulates the production of MMP-2, -9 and -13 in human cartilage [67] .
Furthermore, heparin-binding NH2-terminal and COOH-terminal fibronectin fragments have been reported to induce NO production along with iNOS expression in human chondrocyte monolayer cultures and in arthritic cartilage respectively [68, 69] . It is also demonstrated that these fibronectin fragments also take part in inflammation during arthritis by enhancing the release of proinflammatory cytokines including TNF-α and IL-1β by synovial cells [70, 64] .
Conclusions
Cartilage degradation is an inherent phenomenon of arthritis along with chronic inflammation and it has been a key in the diagnosis and monitoring of the disease progression. It is demonstrated that both enzymatic and non-enzymatic factors significantly contribute to the degradation of cartilage. MMPs, HAases and aggrecanases are the important enzymatic factors while, ROS/RNS are major non-enzymatic factors. Furthermore, cartilage degradation fragments have also been shown to play a key role in cartilage destruction. These fragments are known to activate chondrocytes and synovial fibroblasts resulting in augmented secretion of MMPs, HAase, NO, and proinflammatory modulators leading to aggravated inflammation. However, meticulous understanding of molecular mechanisms of proteases, glycosidases and matrix degradation products would certainly help to prevent cartilage degradation and inflammation in arthritis. 
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